Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Trevi Therapeutics (TRVI) PT Lowered to $8 at Needham & Company
November 11, 2021 6:47 AM ESTNeedham & Company analyst Serge Belanger lowered the price target on Trevi Therapeutics (NASDAQ: TRVI) to $8.00 (from $10.00) while maintaining a Buy rating.
The analyst commented, "TRVI reported 3Q21 financials and provided a corporate update. The ph 2b/3 PRISM trial, evaluating Haduvio (nalbuphine ER) as... More
Trevi Therapeutics (TRVI) Tops Q3 EPS by 6c
November 10, 2021 4:27 PM ESTTrevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.34), $0.06 better than the analyst estimate of ($0.40).
For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.
... More